Supplementary Materials

Impact of financial medication assistance on medication adherence: a systematic review

Anna Hung, PharmD, PhD, MS, Dan V. Blalock, PhD , Julie Miller, BS, Jaime McDermott, MSN, DNP candidate, Hannah Wessler, BS, MS candidate, Megan M. Oakes, MS, Shelby D. Reed, PhD, Hayden B. Bosworth, PhD, Leah L. Zullig, PhD

Supplementary Table 1

Supplementary Table 2

Supplemental Table 1a. Search terms in MEDLINE (via PubMed)

Set #	Search terms	Results
1	"Patient compliance"[Mesh] OR compliance[tw] OR noncompliance[tw] OR non-compliance[tw] OR compliant[tw] OR noncompliant[tw] OR non-compliant[tw] OR "medication adherence"[Mesh] OR adherence[tw] OR nonadherence[tw] OR non-adherence[tw] OR "Medication Therapy Management"[Mesh] OR "medication management"[tw] OR "drug therapy management"[tw] OR "medication persistence"[tw]	302,008
2	coupon[tw] OR coupons[tw] OR rebate[tw] OR rebates[tw] OR discount[tw] OR discounts[tw] OR "patient assistance"[tw] OR "medication assistance"[tw] OR "financial assistance"[tw] OR voucher[tw] OR vouchers[tw]	9,369
3	"Pharmaceutical Preparations"[Mesh] OR "Drug therapy"[Mesh] OR drug[tw] OR drugs[tw] OR medication[tw] OR medications[tw] OR medicine[tw] OR prescription[tw] OR prescriptions[tw]	7,168,700
4	1 AND 2 AND 3	299
5	3 NOT (animals[mh] NOT humans[mh])	298

Supplemental Table 1b. Search terms in Web of Science (via Clarivate Analytics)*

Set #	Search terms	Results
1	TS=(Compliance OR noncompliance OR non-compliance OR compliant OR noncompliant OR non-compliant OR adherence OR nonadherence OR non-adherence OR "medication management" OR "drug therapy management" OR "medication persistence")	354,348

2	TS=(coupon OR coupons OR rebate OR rebates OR discount OR discounts OR "patient assistance" OR "medication assistance" OR "financial assistance" OR voucher OR vouchers)	54,327
3	TS=(drug OR drugs OR medication OR medications OR medicine OR prescription OR prescriptions)	2,495,913
4	1 AND 2 AND 3	358

***** Exclusion of animal studies in Web of Science is difficult as there are no keywords assigned in this database. It is therefore advised not to try to exclude animal studies here.

Supplemental Table 2. Quality Assessment of Studies based on Mixed Methods Appraisal Tool

Author Year (Journal)	Category of study designs	Methodological quality criteria	Responses		
			Yes	No	Can't Tell
Marrs 2008[19] (Pharmacotherapy)	3. Quantitative non-randomized	3.1. Are the participants representative of the target population?	X		
		3.2. Are measurements appropriate regarding both the outcome and intervention (or exposure)?	X		
		3.3. Are there complete outcome data?	X		
		3.4. Are the confounders accounted for in the design and analysis?		X	
		3.5. During the study period, is the intervention administered (or exposure occurred) as intended?	X		
Schoen 2011[20] (Pharmacotherapy)	3. Quantitative non-randomized	3.1. Are the participants representative of the target population?	X		
		3.2. Are measurements appropriate regarding both the outcome and intervention (or exposure)?	X		
		3.3. Are there complete outcome data?	X		
		3.4. Are the confounders accounted for in the design and analysis?		X	
		3.5. During the study period, is the intervention administered (or exposure occurred) as intended?	X		
Knott 2015[21] (Health Policy)	3. Quantitative non-randomized	3.1. Are the participants representative of the target population?	X		
		3.2. Are measurements appropriate regarding both the outcome and intervention (or exposure)?	X		
		3.3. Are there complete outcome data?	X		
		3.4. Are the confounders accounted for in the design and analysis?	X		
		3.5. During the study period, is the intervention administered (or exposure occurred) as intended?	X		
Daugherty 2013[22] (JMCP)	3. Quantitative non-randomized	3.1. Are the participants representative of the target population?	X		
		3.2. Are measurements appropriate regarding both the outcome and intervention (or exposure)?	X		
		3.3. Are there complete outcome data?	X		
		3.4. Are the confounders accounted for in the design and analysis?		X	
		3.5. During the study period, is the intervention administered (or exposure occurred) as intended?	X		
Daubresse 2017[23] (Pharmacotherapy)	3. Quantitative non-randomized	3.1. Are the participants representative of the target population?	X		
		3.2. Are measurements appropriate regarding both the outcome and intervention (or exposure)?	X		

		3.3. Are there complete outcome data?	X		
		3.4. Are the confounders accounted for in the design and analysis?		X	
		3.5. During the study period, is the intervention administered (or exposure occurred) as intended?	X		
Wang 2019[24] (JAMA)	2. Quantitative randomized controlled trials	2.1. Is randomization appropriately performed?	X		
		2.2. Are the groups comparable at baseline?	X		
		2.3. Are there complete outcome data?	X		
		2.4. Are outcome assessors blinded to the intervention provided?	X		
		2.5 Did the participants adhere to the assigned intervention?	X		
Fanaroff 2020[25] (JAMA Cardiology)	3. Quantitative non-randomized	3.1. Are the participants representative of the target population?	X		
		3.2. Are measurements appropriate regarding both the outcome and intervention (or exposure)?	X		
		3.3. Are there complete outcome data?	X		
		3.4. Are the confounders accounted for in the design and analysis?	X		
		3.5. During the study period, is the intervention administered (or exposure occurred) as intended?	X		
Seetasith 2019[26] (Journal of Medical Economics)	3. Quantitative non-randomized	3.1. Are the participants representative of the target population?	X		
		3.2. Are measurements appropriate regarding both the outcome and intervention (or exposure)?	X		
		3.3. Are there complete outcome data?	X		
		3.4. Are the confounders accounted for in the design and analysis?	X		
		3.5. During the study period, is the intervention administered (or exposure occurred) as intended?	X		